TY - JOUR
T1 - Associations of Serum Calciprotein Particle Size and Transformation Time With Arterial Calcification, Arterial Stiffness, and Mortality in Incident Hemodialysis Patients
AU - Chen, Wei
AU - Fitzpatrick, Jessica
AU - Monroy-Trujillo, Jose M.
AU - Sozio, Stephen M.
AU - Jaar, Bernard G.
AU - Estrella, Michelle M.
AU - Serrano, Jishyra
AU - Anokhina, Viktoriya
AU - Miller, Benjamin L.
AU - Melamed, Michal L.
AU - Bushinsky, David A.
AU - Parekh, Rulan S.
N1 - Funding Information:
Wei Chen, MD, MS, Jessica Fitzpatrick, PhD, Jose M. Monroy-Trujillo, MD, Stephen M. Sozio, MD, MHS, MEHP, Bernard G. Jaar, MD, MPH, Michelle M. Estrella, MD, MHS, Jishyra Serrano, BS, Viktoriya Anokhina, MS, Benjamin L. Miller, PhD, Michal L. Melamed, MD, MHS, David A. Bushinsky, MD, and Rulan S. Parekh, MD, MS. Research idea and study design: WC, JF, DAB, RSP; data acquisition: JF, JMM-T, SMS, BGJ, MME, JS, VA, BLM; data processing/analysis/interpretation: WC, JF, MLM, DAB, RSP; statistical analysis: WC, JF, RSP; mentorship: DAB, RSP. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. The PACE Study was funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, R01 DK072367), National Kidney Foundation of Maryland, and by NIDDK (DK090070). Dr Chen is supported by the American Society of Nephrology Carl W. Gottschalk Research Grant and NIDDK (K23 DK114476). Dr Bushinsky is supported by NIDDK (R01 DK075462). Dr Parekh is supported by the Canada Research Chair in chronic kidney disease epidemiology. The Dynamic Light Scattering DynaPro Plate Reader II was supported by National Center for Research Resources grants 1S10 RR026501 and 1S10 RR027241, as well as National Institute of Allergy and Infectious Diseases P30 AI078495 and the School of Medicine and Dentistry, University of Rochester. The funding agencies did not have a role in study design, data collection, analysis, reporting, or the decision to submit for publication. Dr Bushinsky is a consultant for Relyspa/Vifor/Fresenius, Amgen, Sanofi/Genzyme, and Tricida and has an equity interest in Amgen and Tricida. Dr Miller is a consultant for Dodo Omnidata. The remaining authors declare that they have no relevant financial interests. We thank participants, nephrologists, and staff of the DaVita and MedStar dialysis units in the Baltimore region who contributed to the PACE Study. Received December 12, 2019. Evaluated by 3 external peer reviewers, with direct editorial input from a Statistics/Methods Editor and an Associate Editor, who served as Acting Editor-in-Chief. Accepted in revised form May 20, 2020. The involvement of an Acting Editor-in-Chief was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.
Funding Information:
The PACE Study was funded by National Institute of Diabetes and Digestive and Kidney Diseases ( NIDDK , R01 DK072367 ), National Kidney Foundation of Maryland, and by NIDDK ( DK090070 ). Dr Chen is supported by the American Society of Nephrology Carl W. Gottschalk Research Grant and NIDDK ( K23 DK114476 ). Dr Bushinsky is supported by NIDDK ( R01 DK075462 ). Dr Parekh is supported by the Canada Research Chair in chronic kidney disease epidemiology. The Dynamic Light Scattering DynaPro Plate Reader II was supported by National Center for Research Resources grants 1S10 RR026501 and 1S10 RR027241 , as well as National Institute of Allergy and Infectious Diseases P30 AI078495 and the School of Medicine and Dentistry, University of Rochester . The funding agencies did not have a role in study design, data collection, analysis, reporting, or the decision to submit for publication.
Publisher Copyright:
© 2020 National Kidney Foundation, Inc.
PY - 2021/3
Y1 - 2021/3
N2 - Rationale & Objective: Characteristics of the transformation of primary to secondary calciprotein particles (CPPs) in serum, including the size of secondary CPP (CPP2) aggregates and the time of transformation (T50), may be markers for arterial calcification in patients undergoing hemodialysis (HD). We examined the associations of CPP2 aggregate size and T50 with arterial calcification in incident HD patients. Study Design: Prospective cohort study. Setting & Participants: Incident HD patients (n = 402 with available CPP2 measures and n = 388 with available T50 measures) from the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) Study Predictors: Serum CPP2 size and T50 at baseline. Outcomes: Primary outcomes were baseline coronary artery and thoracic aorta calcifications. Exploratory outcomes included baseline arterial stiffness, measured by pulse wave velocity (PWV) and ankle brachial index, and longitudinally, repeat measures of PWV and all-cause mortality. Analytical Approach: Tobit regression, multiple linear regression, Poisson regression, linear mixed-effects regression, and Cox proportional hazards regression. Results: Mean age was 55 ± 13 years, 41% were women, 71% were Black, and 57% had diabetes mellitus. Baseline CPP2 size and T50 were correlated with baseline fetuin A level (r = −0.59 for CPP2 and 0.44 for T50; P < 0.001 for both), but neither was associated with baseline measures of arterial calcification or arterial stiffness. Baseline CPP2 size and T50 were not associated with repeat measures of PWV. During a median follow-up of 3.5 (IQR, 1.7-6.2) years, larger CPP2 was associated with higher risk for mortality (HR, 1.17 [95% CI, 1.05-1.31] per 100 nm larger CPP2 size) after adjusting for demographics and comorbid conditions, but there was no association between baseline T50 and risk for mortality. Limitations: Possible imprecision in assays, small sample size, limited generalizability to incident HD populations with different racial composition, and residual confounding. Conclusions: In incident HD patients, neither CPP2 size nor T50 was associated with prevalent arterial calcification and stiffness. Larger CPP2 was associated with risk for mortality, but this finding needs to be confirmed in future studies.
AB - Rationale & Objective: Characteristics of the transformation of primary to secondary calciprotein particles (CPPs) in serum, including the size of secondary CPP (CPP2) aggregates and the time of transformation (T50), may be markers for arterial calcification in patients undergoing hemodialysis (HD). We examined the associations of CPP2 aggregate size and T50 with arterial calcification in incident HD patients. Study Design: Prospective cohort study. Setting & Participants: Incident HD patients (n = 402 with available CPP2 measures and n = 388 with available T50 measures) from the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) Study Predictors: Serum CPP2 size and T50 at baseline. Outcomes: Primary outcomes were baseline coronary artery and thoracic aorta calcifications. Exploratory outcomes included baseline arterial stiffness, measured by pulse wave velocity (PWV) and ankle brachial index, and longitudinally, repeat measures of PWV and all-cause mortality. Analytical Approach: Tobit regression, multiple linear regression, Poisson regression, linear mixed-effects regression, and Cox proportional hazards regression. Results: Mean age was 55 ± 13 years, 41% were women, 71% were Black, and 57% had diabetes mellitus. Baseline CPP2 size and T50 were correlated with baseline fetuin A level (r = −0.59 for CPP2 and 0.44 for T50; P < 0.001 for both), but neither was associated with baseline measures of arterial calcification or arterial stiffness. Baseline CPP2 size and T50 were not associated with repeat measures of PWV. During a median follow-up of 3.5 (IQR, 1.7-6.2) years, larger CPP2 was associated with higher risk for mortality (HR, 1.17 [95% CI, 1.05-1.31] per 100 nm larger CPP2 size) after adjusting for demographics and comorbid conditions, but there was no association between baseline T50 and risk for mortality. Limitations: Possible imprecision in assays, small sample size, limited generalizability to incident HD populations with different racial composition, and residual confounding. Conclusions: In incident HD patients, neither CPP2 size nor T50 was associated with prevalent arterial calcification and stiffness. Larger CPP2 was associated with risk for mortality, but this finding needs to be confirmed in future studies.
KW - CPP size
KW - Calciprotein particle (CPP)
KW - ankle brachial index (ABI)
KW - arterial calcification
KW - arterial calcification (CAC)
KW - arterial stiffness
KW - calcium phosphate particles
KW - end-stage renal disease (ESRD)
KW - fetuin A
KW - hemodialysis (HD)
KW - mortality
KW - serum albumin
KW - thoracic aortic calcification (TAC)
KW - transformation time
KW - vascular calcification
UR - http://www.scopus.com/inward/record.url?scp=85092224703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092224703&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2020.05.031
DO - 10.1053/j.ajkd.2020.05.031
M3 - Article
C2 - 32800846
AN - SCOPUS:85092224703
SN - 0272-6386
VL - 77
SP - 346
EP - 354
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 3
ER -